An update from Opko Health ( (OPK) ) is now available.
On March 10, 2025, OPKO Health and its subsidiary BioReference Health entered into an agreement to sell certain assets of BioReference’s oncology and oncology-related clinical testing services to Laboratory Corporation of America Holdings (Labcorp) for up to $225 million. This transaction, expected to close in the second half of 2025, is anticipated to enhance Labcorp’s leadership in oncology and expand its laboratory services, while OPKO Health aims to streamline operations and focus on its core clinical testing services in New York and New Jersey.
More about Opko Health
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company that aims to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.
YTD Price Performance: 26.90%
Average Trading Volume: 4,927,684
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.24B
See more data about OPK stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com